

Genet 1997;16:235-42.

40. McCright B, Lozier J, Gridley T. A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. *Development* 2002;129:1075-82.
41. Tanimizu N, Miyajima A. Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. *J Cell Sci* 2004;117:3165-74.
42. Enzan H, Himeno H, Hiroi M, Kiyoku H, Saibara T, Onishi S. Development of hepatic sinusoidal structure with special reference to the Ito cells. *Microsc Res Tech* 1997;39:336-49.
43. Sasaki K, Sonoda Y. Histometrical and three-dimensional analyses of liver hematopoiesis in the mouse embryo. *Arch Histol Cytol* 2000;63:137-46.
44. Shiojiri N. Development and differentiation of bile ducts in the mammalian liver. *Microsc Res Tech* 1997;39:328-35.
45. Clotman F, Jacquemin P, Plumb-Rudewicz N, Pierreux CE, Van der Smissen P, Dietz HC, Courtoy PJ, Rousseau GG, Lemaigre FP. Control of liver cell fate decision by a gradient of TGF beta signaling modulated by Onecut transcription factors. *Genes Dev* 2005;19:1849-54.
46. Kamiya A, Kinoshita T, Ito Y, Matsui T, Morikawa Y, Senba E, Nakashima K, Taga T, Yoshida K, Kishimoto T, Miyajima A. Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer. *Embo J* 1999;18:2127-36.
47. Hara T, Nakano Y, Tanaka M, Tamura K, Sekiguchi T, Minehata K, Copeland NG, Jenkins NA, Okabe M, Kogo H, Mukouyama Y, Miyajima A. Identification of podocalyxin-like protein 1 as a novel cell surface marker for hemangioblasts in the murine aorta-gonad-mesonephros region. *Immunity* 1999;11:567-78.
48. Kitamura T, Onishi M, Kinoshita S, Shibuya A, Miyajima A, Nolan GP. Efficient screening of retroviral cDNA expression libraries. *Proc Natl Acad Sci U S A* 1995;92:9146-50.
49. Chida D, Miura O, Yoshimura A, Miyajima A. Role of cytokine signaling molecules in erythroid differentiation of mouse fetal liver hematopoietic cells: functional analysis of signaling molecules by retrovirus-mediated expression. *Blood* 1999;93:1567-78.
50. Nakamura K, Nonaka H, Saito H, Tanaka M, Miyajima A. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. *Hepatology* 2004;39:635-44.
51. Miyaoka Y, Tanaka M, Naiki T, Miyajima A. Oncostatin M inhibits adipogenesis through the RAS/ERK and STAT5 signaling pathways. *J Biol Chem* 2006;281:37913-20.




Fig.1 Suzuki et.al




Fig.2 Suzuki et.al





Fig.3 Suzuki et.al





Fig.4 Suzuki et.al



E

	E11.5	E14.5	E18.5	neonate
ratio of lipid-containing cells	3.1 %	11.8 %	32.8 %	27.1 %

Fig.4 Suzuki et.al






Fig.5 Suzuki et.al




Supplemental Figure 1 Suzuki et.al




Flow chart for screening of antibodies

Supplemental Figure 2 Suzuki et.al



Supplemental Figure 3 Suzuki et.al



Supplemental Figure 4 Suzuki et.al